Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (kupffer cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: rocacetrapib, obicetrapib, evacetrapib +3 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 3,269 | 0.79 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9804
Sealed predictions
- CETP in dopamine neurons, braak-0.49 (p 0.182) → +0.03 (p 0.929)receipt 9812
Swarm cases
receipt 9812: CETP in dopamine neurons, braak
- power
- full sample -0.30 (p 0.228, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.044, n 18). not the mix.
- skeptic
- leave-one-out range -0.45 to -0.21, sign flips 0; without severely affected donors -0.30 (p 0.228, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CETP in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts